Lilly won't hike SGX offer; GSK lays off more in Carolina;

> Eli Lilly said Monday it will not raise its buyout price for biotechnology company SGX Pharmaceutical, describing its bid of $3-per-share bid as its "best and final offer." Report

> GlaxoSmithKline laid off 22 more employees at its North Carolina research facility following an earlier summer dismissal of 100 scientific workers. Report

> Bayer filed a patent infringement lawsuit to prevent Novartis' generic drugs unit Sandoz from selling a copycat version of the German group's oral contraceptive YAZ in the United States. Report

> Boehringer Ingelheim said its Aptivus AIDS drug was shown to be effective and safe for children and adolescents in a two-year study involving 78 patients who had previously received other treatments. Report

> Medicines Co. got FDA approval to market its injectable drug Cleviprex for patients with difficult-to-treat high blood pressure. Report

> Ranbaxy Laboratories said that the World Health Organization had included another of its HIV-fighting drugs on its prequalification list, bringing the number of its AIDS meds on that list to 18. Report

> A drug used to fight tuberculosis also hampers the effectiveness of an HIV treatment widely used in Africa, the world's worst AIDS-hit region, a new study said. Report

> Madison, WI-based OpGen, which has developed new technology to map a microorganism's genome, is moving to Montgomery County in Maryland and plans to swiftly ramp up operations with new hires. OpGen report

> The tiny, Portland-based developer Dimera tells the local Business Journal that the company needs to raise $40 million in order to survive. Dimera report

> Schering-Plough published promising new data for its experimental hepatitis C drug boceprevir, which pushed down the share value of rival Vertex Pharmaceuticals. Report

> The largely unknown TauRx has been basking in the limelight of some startling efficacy data for its experimental Alzheimer's drug--Rember. Now TauRx officials tell The Times that ongoing discussions may soon lead to new partnerships. Report

And Finally... Megadoses of vitamin C halved the size of tumors in mice, a new study shows. Report

Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.